Rebecca Pedersini
Brescia, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 69 publications
Adiposity Excess and Vertebral Fractures in Patients With Breast Cancer Taking Aromatase Inhibitors.
Adiposity Excess and Vertebral Fractures in Patients With Breast Cancer Taking Aromatase Inhibitors.
Journal: JAMA network open
Published: July 30, 2026
Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 14, 2026
Circulating tumor cells predict early skeletal-related events in patients with bone metastases from breast cancer.
Journal: The journal of liquid biopsy
Published: May 21, 2026
Prolonged survival in a HER2 positive metastatic breast cancer patient with brain metastases treated with TDM1 after failure of next generation HER2 targeted therapies: case report.
Journal: Frontiers in oncology
Published: April 26, 2026
Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 23, 2025
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study.
Journal: Breast (Edinburgh, Scotland)
Published: December 22, 2025
From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching.
Journal: Tumori
Published: December 15, 2025
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2.
Journal: Breast (Edinburgh, Scotland)
Published: November 12, 2025
Predictors of survival outcomes in patients with neuroendocrine neoplasms: a real-world retrospective study.
Journal: Endocrine-related cancer
Published: July 03, 2025
Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.
Journal: The oncologist
Published: June 13, 2025
Fracture risk in metastatic breast cancer patients treated with CDK 4/6 inhibitors and endocrine therapy.
Journal: Breast cancer research and treatment
Published: April 14, 2025
Last Updated: 09/26/2026